MC

McKesson Corporation

MCKHealthcareNASDAQ

Medical Distribution · Last scanned Oct 26, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$403.43B
+12.4% YoY
Net Income
$4.76B
+44.5% YoY
EBITDA
$7.18B
+36.4% YoY
Free Cash Flow
$6.80B

Scan Results

Daily timeframe
10 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20CONFIRMED▼ RSI OverboughtRSI 88.3, above 70, stock may be overbought
Oct 19CONFIRMED▼ RSI OverboughtRSI 88.4, above 70, stock may be overbought
About McKesson Corporation

McKesson Corporation provides healthcare services in the United States and internationally. The company carries a $116.68B market cap, placing it firmly in the large-cap category. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

Where MCK stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, MCK finished 20.17% above its 150-day moving average ($840.85) and 18.38% above its 200-day moving average ($853.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is MCK overbought or oversold?

At the October 20, 2026 close, MCK's RSI(14) was 88.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$116.68B
P/E (TTM)26.82
Fwd P/E19.77
EPS$37.31
Beta0.30
52W Change+23.3%
Dividend Yield0.38%
Analysis

The company holds $5.16B in cash, though total debt stands at $11.80B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $6.80B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $276.71B (2023) to $403.43B (2026), reflecting a 46% increase over the period.

The relatively low beta of 0.30 suggests MCK is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing MCK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms